FDA Approves Raxibacumab for Treating Inhalable Anthrax

by Kathy Jones on  December 15, 2012 at 9:07 PM Drug News
RSS Email Print This Page Comment
Font : A-A+

GlaxoSmithKline's injectable drug. raxibacumab, has been approved by the US Food and Drug Administration for treating inhalable anthrax.

Inhalation of anthrax is seen as a major bioterrorism risk and is caused when people inhale spores of anthrax bacteria.
 FDA Approves Raxibacumab for Treating Inhalable Anthrax
FDA Approves Raxibacumab for Treating Inhalable Anthrax

Raxibacumab has been developed by GSK's Human Genome Sciences and is a man-made protein that works by mimicking the naturally produced antibodies and blocks the toxins produced by the anthrax bacteria



Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Anthrax Bioterrorism 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive